Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
Conclusions/interpretationIn individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications. However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors.Graphical Abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Alcoholism | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Fortamet | Heart | Heart Attack | Heart Failure | Ischemic Stroke | Liver | Liver Disease | Metformin | Non-alcoholic Fatty Liver Diseases (NAFLD) | SGLT2 Inhibitors | Sodium | Stroke | Study | Urology & Nephrology